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Introduction 
The need for international collaboration in the con- 
duct of research in the clinical management of head 
injury has never been greater. Rigorous evaluation 
must be carried out on a range of approaches that 
include new pharmacological agents - so-called neu- 
roprotective drugs, manipulations of physiological 
conditions, eg hypothermia, nd protocols for aspects 
of management ranging from initial resuscitation a d 
triage to details of intensive care - "guidelines". 
The European Brain Injury Consortium has been 
formed to promote international, multicentre, inter- 
disciplinary research aimed at improving the outcome 
of patients who have suffered a head injury or other 
kind of acute brain damage. This article describes the 
origin, nature and aims of the organisation and its 
initial activities and achievements. 
Background 
The increased understanding of mechanisms of 
brain damage and the development of specific, target- 
ed treatments has drawn the interest of many agen- 
cies. Much of the interest has been focused on 
ischaemic brain damage and many neuropharmaco- 
logical agents have been shown to reduce the amount 
of damage occurring after insults induced experimen- 
tally in the laboratory (McIntosh 1993 [21], Korshitz 
1996 [13]). Interest in applying such treatments o 
head injuries stems from the highlighting of the fre- 
quency of secondary insults (Miller 1978 [22]) of an 
ischaemic nature and their importance in determining 
outcome (Jones 1994 [12], Gopinath 1994 [8]) and 
the evidence that at the molecular, cellular level, the 
mechanisms of ischaemia nd trauma merge (Jenkins 
1989 [9], Cohadon 1994 [5]). Moreover, because 
head injuries are treated urgently and usually moni- 
tored intensively, they are a more appropriate popula- 
tion than stroke victims in which to carry out early 
research in so-called neuroprotective treatments 
(Teasdale and Bannon 1997 [26]). 
Many of the new approaches stem from extensive 
development programmes conducted by pharmaceuti- 
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cal companies. Often, head injury is a new area for a 
company which thus lacks "in-house" expertise about 
such crucial factors in clinical trials as the selection of 
patients to study, the data to collect, and the way to 
assess outcome. Thus, the lack of experience may 
extend to knowledge of the appropriate sources for 
advice, leading to a temptation to contact clinicians 
because they are either geographically convenient or 
have previously collaborated in another area of 
research. Understandable enthusiasm, unhindered by 
experience and understanding of research in the man- 
agement of head trauma, has led to instances of proto- 
cols being developed in detail before they have been 
presented for general scrutiny. The ensuing conflicts 
between protocols that are "set in stone" and the wis- 
dom and knowledge of experienced investigators 
about what will actually work in practice, can lead at 
best to frustration and irritation, at worst to conflict 
and impasse. The need to avoid and to deal with these 
tensions and to bring a strong, independent clinical, 
scientific perspective to the conduct of research in 
this field, led in 1994 to the development of consortia 
of investigators in North America (Marmarou 1996 
[16]) and Europe. This article describes the evolution 
and initial activities of the European Brain Injury 
Consortium. 
Precedents 
The formation of the European Association of 
Neurosurgical Societies in 1971 promoted clinical 
and scientific ontacts and discussions between Euro- 
pean neurosurgeons. The institution by the World 
Federation of Neurosurgical Societies of an "ad hoc" 
Committee on Head Injuries in 1965 followed by the 
establishment of a Committee of Neuro-Traumatol- 
ogy in 1977, provided aworldwide focus on the prob- 
lems of neurotrauma. Some of the first fruits of inter- 
national co-operation took the form of retrospective 
studies of cohorts of patients, typified by the compar- 
ative Scottish/Dutch studies of patients with com- 
pound depressed fracture (Braakman and Jennett 
1975 [2]). Scottish and Dutch centres were also 
involved with centres in the west coast of America in 
early prospective international studies, the so-called 
International Traumatic Coma Data Bank (Jennett 
1977 [11], Murray 1986 [24]). These studies led to the 
development of methods of description of severity of 
injury (Teasdale and Jennett 1974 [27]), and of 
assessing outcome (Jennett and Bond 1975 [10]), that 
became standards (Langfitt 1978 [14]) for subsequent 
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studies. The North American Traumatic Coma Data 
Bank (Marshall 1983 [17]) aimed to explore in 
greater depth and detail the pathophysiology of the 
acute stage, for example in regard to intracranial pres- 
sure, cerebral perfusion pressure, secondary insults, 
and CT scan classification and their relations to out- 
come (Marshall 1991 [18]). 
The methods developed in the foregoing observa- 
tional studies (Miller and Teasdale 1985 [23]) were 
applied to local and national trials (e.g., Braakman 
1983 [3]), and then to a prospective randomised inter- 
national control trial of a calcium antagonist in severe 
head injuries by a British/Finnish group (Bailey et al.  
1991 [1]). This study showed atrend to benefit but the 
population studied was insufficient for adequate sta- 
tistical power. The performance of a further study 
required the involvement of a larger number of units 
in more European countries (The European Collabo- 
rative Study of Nimodipine 1994 [28]). This study 
recruited 852 patients in 21 units in 13 countries and 
proved the feasibility of multi-centre, multinational 
European collaborative trials while also providing 
insights into their problems. 
The Gestation of "EBIC" 
The concept of an European organisation was pro- 
posed at a meeting held on 1st October 1993 in Lon- 
don. Although composed principally of investigators 
from British neurosurgical nd neurointensive care 
units, the meeting was also attended by representa- 
tives from other European countries. There was a 
clear consensus that, while individual countries 
should continue internal collaborations, the overrid- 
ing priority was for an European-wide organisation. 
This reflected the realisation that the numbers of 
patients required in the design of definitive Phase III 
studies of severe head injury demanded European- 
wide recruitment. I  also reflected the perception that 
an organisation ofthis scope and scale - both in terms 
of numbers of centres and expertise of investigators - 
would be able to conduct fruitful negotiations on cru- 
cial scientific factors with multinational pharmaceuti- 
cal companies and other sponsors of research. 
The first preparatory meeting for the European- 
wide organisation was held in Amsterdam on 5th 
February 1994. Invitations were issued to neurosur- 
geons and neurointensivists who were known to have 
an interest in research in head injuries, either because 
they had participated in previous studies, or had a 
record of publication and research. The meeting was 
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attended by representatives from 40 centres in 10 
countries who agreed to set up a small working party 
to prepare and report on further plans. At a second 
meeting on 19th March 1994 these provisional pro- 
posals were endorsed and the meeting charged a 
steering committee with the duty of bringing back 
detailed proposals for formal deliberation at the time 
of the meeting of the European Association of Neuro- 
surgical Societies in 1995. In the meantime, the steer- 
ing committee were authorised to initiate discussions 
and planning for scientific activities. The steering 
committee's proposals were presented toa meeting in 
Berlin on 9th May 1995 attended by 36 neurosur- 
geons and neurointensivists from 10 countries. After 
thoughtful and serious discussion, the proposals were 
accepted and the European Brain Injury Consortium 
became formally constituted. 
The Aims of "EBIC" 
1. To promote and to conduct research aimed at 
improving the outcome of patients with acute brain 
injury; to bring a strong, independent clinical per- 
spective to the evaluation of new treatments. 
2. To establish close co-operation between European 
head injury centres and investigators in the man- 
agement of severe head injury and other types of 
acute brain damage. 
3. To negotiate with, and to work in partnership with 
sponsors to ensure excellence in the design, con- 
duct, analysis and publication of clinical trials in 
neuroprotection. 
4. To act as an advisory organ both in practical and 
theoretical issues concerning all kinds of brain 
injury studies. 
Structure 
It was recognised that an informal, loose associa- 
tion would no longer serve to meet he challenges and 
responsibilities of the new organisation. This was not 
least because there was a need to develop aclear iden- 
tity, focus, and status in discussions and negotiations 
with outside bodies. At the same time, there was a 
desire to avoid an overly formal, rigid structure with 
excessive administrative encumbrances. There was 
also recognition that although the organisation should 
be wide-spread throughout Europe, the reality was 
that levels of interest and commitment tohead injury 
research varied and that a strictly geographically/ 
politically representative structure was both inappro- 
priate and even potentially divisive. 
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The reference to the organisation as a "Consor- 
tium" came after considerable discussion and even 
consultation with the Oxford English Dictionary 
which defined aConsortium as a temporary co-opera- 
tion of several powers or large interests to effect some 
common purpose. The term seemed preferable to 
other choices such as Society, Co-operative or even 
Cartel! It reflected also the development of many 
similarly termed groups in various aspects of medi- 
cine. A search of a database (Bath Information and 
Data Services) in January 1997 disclosed references 
to 39 medical consortia, those in the neurosciences 
include genetics, muscular dystrophy, stroke, epilep- 
sy, brain turnouts and dementia. 
The steering committee of the Consortium 
received strong legal advice that, whatever the organ- 
isation's title or structure, it could be seen as acting as 
an identifiable body, incurring responsibilities and 
liabilities that could fall on each individual who in 
any way participated in its activities. The steering 
committee therefore accepted the advice that he Con- 
sortium should establish itself as a registered compa- 
ny, number SC 159579, with the liabilities of the indi- 
vidual members of the company limited by guarantee 
to a maximum sum of s Furthermore, it was pro- 
posed and accepted that the required named irectors 
and members of such a company should consist of 
participants in the then steering committee or their 
successors in the Executive of the Consortium. The 
benefits of these arrangement were seen to be the 
avoidance of potential personal financial liability, the 
establishment of EBIC as a legally recognised body, 
able to form agreements with other bodies of a more 
formal nature, and the removal of the need to identify 
by name each individual potentially participating in
activities of the Consortium. These were considered 
to outweigh the potential disadvantages in terms of 
formalisation and organisational complexity. An 
additional advantage, recently achieved, has been that 
the organisation has been able to apply successfully 
for recognition as a Scottish Charity (No SC025721). 
The aim in the establishment of the organisational 
structure and the central Executive of the Consortium 
was to facilitate co-operation and communication 
amongst the wider membership, both between indi- 
vidual centres and between them and potential spon- 
sors of studies. In order to achieve this, the Consor- 
tium has established a central co-ordinating centre, 
with an administrator, based in the University of 
Glasgow. The administrator is responsible for com- 
munication with members, including regular newslet- 
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ters, and for organisation of meetings of the Execu- 
tive, which have been held at 1-2 month intervals 
through 1995 and 1996. Detailed initial discussions 
about potential projects are conducted by the Execu- 
tive, for each potential study a specific working party 
is set up, whose aim is to draw up a suitable scientific 
protocol for presentation to members. On the other 
hand, it is a principle of the Consortium that negotia- 
tions regarding the participation of an individual cen- 
tre in the study are conducted irectly between the 
representatives of that centre and the sponsor, and for- 
malised in a contract between these parties without 
the intervention of the Consortium. 
Membership 
Investigators from over 120 centres in 22 countries 
have expressed an interest in participating in the 
activities of EBIC (Fig. 1, Appendix 1). In accord 
with the foregoing organisational structure, no 
attempt so far has been made to establish criteria for 
centres which are "members". On the other hand, the 
realities of research, in particular its sources of fund- 
ing, have meant hat so far is has not been possible for 
all interested centres to have become "active" centres. 
Pharmaceutical companies, in particular, have strong 
preferences for carrying out research in particular 
countries or regions. This reflects considerations that 
include the sponsor's pre-existing infrastructure and 
the time factors involved in regulatory processes in 
different parts of Europe, as well as the capabilities of 
a centre for studies of varying technological complex- 
ity. 
Fig. 1. 
Core Data Study 
The feasibility of collaborative r search in such a 
large number of European centres was tested in a 
"Pilot Core Data Study". A two page proforma was 
designed, using previous experience, to capture a 
minimum of data on the early severity and manage- 
ment complications of adult severely injured patients 
- defined as not obeying commands. Interested cent- 
res were invited to use the proforma to record infor- 
mation about patients admitted to their centre over a 
two month period and 67 centres ubmitted data from 
just over 1000 patients. The preliminary results were 
presented at several meetings and confirmed the high 
commitment to the activities of the Consortium. The 
data were of high quality and credibility and provided 
the most up to date picture of the management of
severely head injured patients in Western society 
(EBIC Core Data Study, J. D. Miller Symposium 
1996, J Neurotrauma 1997, in press [6]). The centres 
who participated in the initial survey were subse- 
quently asked to provide data on outcome of reported 
patients at 6 months after injury. 55 centres (82%) 
provided information from 835 out of 999 patients 
(84%) reported by those centres. Full publication is in 
preparation. Access to information from the study is 
through Professor G. Murray, University of Edin- 
burgh, the statistician on the Executive of the Consor- 
tium. 
Guidelines for Management 
The evidence gained from previous collaborative 
studies (Jennett et al. 1977 [11]), and supported by 
recent publications (Murray 1993 [25], Ghajar 1995 
[7]), that there are considerable variations in practice 
in the management of severe head injuries, prompted 
the development of a set of basic guidelines for use 
within studies arranged through the Consortium 
(Mass et al., Acta Neurochirurgica, 1997 [15]). These 
guidelines were initially drafted in the light of discus- 
sions amongst the Executive, were circulated to all 
interested centres for comment and then revised to 
take account of this feedback. Although the purposes 
of this process were to ensure at least a certain mini- 
mum standard of management, and to promote con- 
sistency between approaches in centres involved in 
clinical trials, the guidelines developed in this way 
should be applicable to routine clinical practice. 
Indeed, these EBIC guidelines evolved by consulta- 
tion, consensus and a "delphic" process how encour- 
aging close correspondence with guidelines recently 
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produced by a North American group as a result of a 
rigorous, evidence-based process (Bullock 1996 [4]). 
Clinical Trials 
Discussions about potential clinical trials in head 
injury have been held between the Executive and rep- 
resentatives of several pharmaceutical companies. 
These have led, so far, to the initiation of two Phase 
III studies and two Phase II studies. The Consortium 
has provided "one door" access to expertise and 
advice about research on the treatment of severe head 
injuries in Europe, with particular inputs to the 
design, conduct and analysis of studies and in the 
selection of centres. This arrangement optimises the 
chances of a study being successful and influential 
but can, of course, carry no guarantee of patient 
recruitment rates or of results. To a participating cen- 
tre, the arrangement has advantages that the proposed 
study has been scrutinised and designed in accord 
with the highest levels of scientific principle and 
practical experience. Some potential studies have not 
been proceeded with, often for reasons more related 
to company policy decisions than scientific or clinical 
potential, but the arrangement can minimize the risk 
of unrewarded effort being expended in preparing for 
a study that does not come to fruition. 
The Consortium's primary concern is with the con- 
cepts and conduct of a study. Its level of practical 
involvement during a study varies according to the 
needs of the study, sponsor and centres. The services 
EBIC provides include the nomination of members of 
steering/management committees, safety and efficacy 
monitoring committees, data analysis and writing 
committees, the monitoring of activity and trial 
recruitment in individual centres through "screening 
logs", review of individual cases for clinical quality, 
centralised interpretation f CT scans and reports of 
adverse vents. A 24 hour "help line" is available for 
advice on difficult decisions about entry of individual 
patients. "Active" centres have been visited by mem- 
bers of the Executive and a detailed atabase of their 
facilities and practical methods compiled as a basis 
for advising sponsors on suitability for studies involv- 
ing different degrees of expertise and technical com- 
plexity. 
Communication and Information 
Communication and collaboration with the North 
American Brain Injury Consortium was begun before 
the formal establishment of EBIC and has been main- 
tained through regular contacts and the attendance of
representatives from each organisation atmeetings of 
its counterpart. This has enabled the adoption on 
either side of the Atlantic of detailed protocols, with 
minimal change, devised on the other. It has also 
facilitated a consistency of approach and advice in 
interaction with sponsoring organisations. Recently, 
in order to enhance dissemination of knowledge of 
the existence of the Consortium and its nature, a"web 
site" has been established: 
(http://www.ed.ac.uk/~gdm/EBIC/). 
The Future 
The level of activity and influence achieved by 
EBIC in its first two years are reasons for consider- 
able satisfaction. Fears at one time that it might be 
stillborn have been dispelled but its continued sur- 
vival and development requires that challenges are 
faced. The activities of both the central organisation- 
al structure and individual centres demand continuing 
resourcing. The attractiveness of the advice of EBIC 
to sponsors does not seem to be in doubt; what cannot 
be foreseen is the extent o which financial manage- 
ment in industry will respond to the advice of clinical 
scientific project eams, either in pursuing research in 
head injury or conducting this through EBIC. The 
benefits of multinational research groups are being 
recognised by governmental sources of support and 
these need to be harnessed tosustain the structure and 
scientific activities of the Consortium. 
The list of centres expressing an interest in the 
Consortium, and in particular those who are "active" 
is not evenly distributed throughout Europe. At pre- 
sent, activity reflects the historical development of
the Consortium largely in North-west European coun- 
tries. Whether the existing distribution also reflects 
levels of the expertise, xperience and commitment to 
head injury research remains to be discovered. One of 
the aims of the Executive is to expand activities more 
widely, how this can be achieved will be determined 
not only by the enthusiasm and contribution of poten- 
tial new centres, but also the availability of new fund- 
ing. Conversely, there is clearly a wide range of level 
of activity in existing "active" centres. For example, 
in the Consortium's major current study (SAPHIR 
Project) more than 36% of patients recruited so far 
come from only 13 % of centres. This might give rea- 
son to question if all existing active centres hould 
remain so, but the information available to the Execu- 
tive has often provided reasons for understanding 
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Appendix 1. The European Brain Injury Consortium European Centres 
Austria Marburg Iasi Augsburg *Turin *Birmingham 
Klagenfurt *Mtinchen Timisom-a *Berlin *Verona *Bristol 
Salzburg-Algen *Mtinster Spain *Bielefeld The Netherlands *Cambridge 
Belgium *Murnau/Obb *Barcelona Bochum *Amsterdam *Cardiff 
Brussels *Ravensburg *Bilbao *Bonn Den Haag *Couventry 
*Gent *Regensburg *Madrid Dortmund *Groningen *Dundee 
*Leuven *Wiesbaden Oviedo *Dresden Heerlen *Edinburgh 
Croatia *Wgrzburg *San~tander *Duisburg *Rotterdam *Glasgow 
Rijeka Greece Sweden *Dtisseldorf Tilburg *Hull 
Denmark Iraklion Gothenburg *Essen *Utrecht *Leeds 
*Aalborg Thessaloniki *Linkoping *Erlangen Norway *Liverpool 
*Copenhagen Hungary *Lund Frankfurt *Bergen *London 
Eire Pecs *Stockholm *Giessen *Trondheim *Manchester 
*Dublin Italy *Umea *G~ttingen Poland *Middtesbrough 
Finland Ancona *Uppsala *Greifswald Krakow *Newcastle 
*Helsinki Bologna Switzerland *Gtinzburg Lublin *Nottingham 
France Bozen *Aarau *Hamburg Poznan *Plymouth 
Bordeaux *Brescia *Basle *Hannover Szszecin *Preston 
Marseilles *Cesena *Berne Heidelberg Warsaw *Salford 
*Montpellier Ferrara *Lausanne *Homburg Wroclaw *Southampton 
*Paris *Milan *Ztirich *Jena Zgierz *Swansea 
*Poitiers *Monza Turkey Kiel Portugal Yugoslavia 
*Reims *Parma Erzurum *K61n Porto *Belgrade 
*Strasbourg *Pavia Istanbul Ltibek Romania 
*Toulouse *Rome UK Mainz Bucharest 
Germany *Treviso Belfast *Mannheim Cluj-Napoca 
* Denotes "active" centre, 
why short term local diff icult ies in faci l i t ies may have 
temporar i ly  l imited patient activity. Conversely,  the 
involvement  and support of new invest igators in pre- 
v iously unknown centres has often been rewarded by 
a high level of  performance in terms of  qual ity and 
quantity of  activity. 
Clearly,  the Consort ium must continue to evolve.  
This pr inciple is promoted in the constitut ion of  the 
Execut ive,  some of  whose original  members  have 
recent ly retired after p lay ing crucial  roles in its for- 
mation,  and with their replacement the Execut ive has 
changed and expanded its representation. At the same 
t ime, the structure of  the Consort ium should enable it 
to cope with f luctuations in the level of  interest and 
activity in indiv idual  centres, especia l ly  to incorpo-  
rate the new part ic ipants who wil l  be necessary to 
br ing the vigour and innovat ion that wil l  be essential  
for it to continue to f lourish. 
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